Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences Inc (NASDAQ: PLSE) pioneers bioelectric medicine through its proprietary Nano-Pulse Stimulation technology, offering investors and medical professionals a novel approach to non-thermal therapies. This dedicated news hub provides real-time updates on clinical advancements, regulatory developments, and strategic partnerships shaping the future of targeted cellular treatments.
Access verified information about PLSE's progress in immuno-oncology applications, dermatology research breakthroughs, and system commercialization efforts. Our curated feed includes earnings reports, FDA submissions, peer-reviewed study results, and executive commentary – all essential for evaluating the company's position in the electroceuticals market.
Key updates cover therapeutic trial milestones, intellectual property expansions, and collaborations with leading medical institutions. Bookmark this page to monitor how PLSE's drug-free energy modalities could transform treatment protocols for complex conditions while driving long-term value in the medical device sector.
Pulse Biosciences (Nasdaq: PLSE) reported significant progress across its three key market development programs utilizing its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology. The company has treated over 140 Benign Thyroid Nodule patients and submitted FDA IDE applications for both cardiac surgical clamp and nsPFA 360° catheter programs.
In cardiac applications, PLSE has treated 40 patients in their surgical AF ablation program and over 140 patients with the nsPFA 360° catheter in Europe, showing positive clinical outcomes. Financial results show Q2 2025 GAAP net loss of $19.2 million, with cash reserves of $106.3 million as of June 30, 2025.
Pulse Biosciences (Nasdaq: PLSE), a pioneer in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has announced its participation in the 45th Canaccord Genuity Annual Growth Conference in Boston. The company's management team will deliver a presentation on August 13, 2025, at 11:00 am ET.
Investors can access both live and recorded versions of the presentation through the company's investor relations website under the "Events Calendar and Presentations" section at investors.pulsebiosciences.com.
Pulse Biosciences (Nasdaq: PLSE), a company focused on Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has scheduled its Q2 2025 business updates and financial results conference call for August 12, 2025, after market close.
The conference call will begin at 1:30 PM PT / 4:30 PM ET. Investors can join via phone using the numbers 1-800-715-9871 or 1-646-307-1963 with passcode 2036874. A live and recorded webcast will be available on the company's investor relations website.
Pulse Biosciences (Nasdaq: PLSE), a nanosecond Pulsed Field Ablation technology company, has granted equity inducement awards to its new principal accounting officer and four other new employees. The Compensation Committee approved a total of 68,217 stock options under the 2017 Inducement Equity Incentive Plan on July 14, 2025.
Steven T. Weber, the new principal accounting officer, received 55,000 options split equally between time-based vesting over four years and performance-based objectives tied to market capitalization goals ranging from $1.5 billion to $4.0 billion. The remaining employees received time-based vesting options over four years. All options have an exercise price of $16.03 per share.
Pulse Biosciences (PLSE), a company specializing in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has granted equity inducement awards to four new employees. The awards, approved on May 19, 2025, consist of stock options to purchase a total of 8,300 shares of company common stock at an exercise price of $17.13 per share, equal to the closing price on the grant date.
The options were granted outside the Company's 2017 Equity Incentive Plan but under the 2017 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards feature a four-year time-based vesting schedule, with 25% vesting annually, contingent on continued employment.
Pulse Biosciences (NASDAQ: PLSE), a pioneer in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has announced its participation in the upcoming BofA Securities 2025 Health Care Conference in Las Vegas. The company's management team will deliver a presentation on Wednesday, May 14, 2025, at 5:00 pm PT. Investors and interested parties can access both live and recorded versions of the presentation through the company's investor relations website at investors.pulsebiosciences.com, specifically on the "Events Calendar and Presentations" page.
Pulse Biosciences (PLSE), specializing in Nanosecond Pulsed Field Ablation™ technology, has announced equity inducement awards for five new employees. The Compensation Committee approved stock options to purchase a total of 19,500 shares of company common stock outside the 2017 Equity Incentive Plan, but under the 2017 Inducement Equity Incentive Plan.
The stock options were granted on April 21, 2025, with an exercise price of $17.29 per share, matching the company's closing stock price on that date. These options will vest over a four-year period, with 25% vesting annually, contingent on continued employment with Pulse Biosciences.
Pulse Biosciences (Nasdaq: PLSE), specializing in Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
The company will host a conference call at 1:30pm PT / 4:30pm ET on the same day. Investors can participate by dialing 1-800-717-1738 or 1-646-307-1865. A live and recorded webcast will be available on the company's investor website.
FAQ
What is the current stock price of Pulse Biosciences (PLSE)?
What is the market cap of Pulse Biosciences (PLSE)?
